Pharmafile Logo
Pharmafocus logo
Advanced Search

Sepha is fast packing with a new EZ Blister upgrade.

September 1, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Packaging Equipment Specialist, Sepha, has released a functional upgrade for one of its original products, EZ Blister, the lab scale …

News
Press release
cloud

Cloud on the horizon: Cloud computing and the clinical trial

September 1, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cloud Computing, ICON, clinical trials, ibm

 Originally published in the September edition of Pharmafocus, Matt Fellows investigates how cloud computing may just be the answer the …

Feature

Eli Lilly elects Jamere Jackson to board of directors

September 1, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, appointment

Eli Lilly has elected Jamere Jackson to its board of directors, effective 1 October, where he will serve on the …

Appointment
novartis_iobmr

Up to 120 jobs set to go as Novartis closes down Cell and Gene Therapies unit

September 1, 2016
Manufacturing and Production, Research and Development CAR-T, Novartis, cart, cell and gene therapies

News has emerged that Novartis plans to close down its Cell and Gene Therapies unit, with up to 120 workers …

News

Lars Rebien Sørensen to retire as CEO of Novo Nordisk

September 1, 2016
Novo Nordisk, appointment

Novo Nordisk has announced that its president and CEO Lars Rebian Sørensen (pictured) is to retire at the end of …

News
roche_close

Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial

September 1, 2016
Research and Development PD-L1, Roche, keytruda, nivolumab, opdivo, phase III, tecentriq

Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …

News
pfizer_chrome_plate

Pfizer nabs EU approval for Xalkori for certain lung cancers

August 31, 2016
Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer

The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …

News

Recipharm establishes long term supply agreement with Tillotts Pharma AG

August 31, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Recipharm, the contract development and manufacturing organisation (CDMO), announces that it has entered into a long term supply agreement with …

News
Press release
pharmafocus_sept_2016_cover

The September issue of Pharmafocus is now live!

August 31, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo

The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …

News

AstraZeneca to pay £5.52 million to settle bribery probe

August 31, 2016
Research and Development AstraZeneca, SEC, misconduct

According to US regulators, AstraZeneca is to pay $5.52 million to resolve a foreign bribery probe investigating payments made to …

News
novartis_building

FDA approves Novartis Enbrel biosimilar

August 31, 2016
Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar, erzeli

Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …

News
teva_copy

Teva to lay off 236 in Pomona, New York

August 30, 2016
Manufacturing and Production, Research and Development Teva, closure

Teva is currently in the process of winding down operations at its manufacturing plant in Pomona, New York as it …

News

UK asthma spending tops £1.1 billion

August 30, 2016
Research and Development asthma, university of edinburgh

The University of Edinburgh has released a report that claims UK health service spending on asthma has reached £1.1 billion …

News
shkreli_kalobios

KaloBios cuts ties with former CEO Martin Shkreli, outlines ‘maniacal’ turnaround plan

August 30, 2016
Research and Development, Sales and Marketing Daraprim, KaloBios, Martin Shkreli, Retrophin, benznidazole, turnaround

Two months after small drugmaker KaloBios returns from bankruptcy, controversial industry figure Martin Shkreli is no longer a stakeholder in …

News
pancreatic_cancer_research

Heart disease drug development is falling

August 30, 2016
Manufacturing and Production, Research and Development cardiovascular disease, heart disease, research and development

The number of drugs currently in development to combat heart disease has fallen in the last 20 years, it has …

News

Cipla receives FDA approval for generic version of Valeant antidepressant

August 30, 2016
Manufacturing and Production, Sales and Marketing Cipla, FDA, Valeant, Wellbutrin

Indian multinational pharma and biotech company Cipla has announced that its US arm InvaGen Pharmaceuticals has received approval from the …

News
amgen_hq

Amgen’s Prolia achieves positive top-line Phase III results after 12 months

August 30, 2016
Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III

Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …

News
clinical_trial-web

Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target

August 30, 2016
Manufacturing and Production, Research and Development Regeneron, Sanofi, apheresis, cholesterol, phase III

Sanofi and Regeneron have announced that their Praluent injection generated positive Phase III results investigating patients with an inherited form …

News
asthma_inhalers

Vectura asthma treatment fails at Phase III

August 30, 2016
Manufacturing and Production, Research and Development asthma, inhaler, phase III, phase III failure, vectura

Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted …

News
top_ten

Top ten stories in the pharmaceutical industry this week

August 26, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile, top 10

If this week left you feeling with a sense of déjà vu, you could certainly be forgiven. With US politicians …

News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026